Aimmune's peanut allergy drug meets main goal of key study

Aimmune's peanut allergy drug meets main goal of key study  Reuters Aimmune Therapeutics' Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut ...  Business Wire (press release) Aimmune Therapeutics (AIMT) Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut ...  StreetInsider.comFull coverage

Read More ...
Aimmune's peanut allergy drug meets main goal of key study published February 20, 2018 at 07:10PM. Original Source Link : https://www.reuters.com/article/aimmune-study/aimmunes-peanut-allergy-drug-meets-main-goal-of-key-study-idUSL4N1QA2SK

loading...